Stock Scorer

Sarepta Therapeutics, Inc. (SRPT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 300M 600M 900M Q3 '21: 189.4M Q4 '21: 201.5M Q1 '22: 210.8M Q2 '22: 233.5M Q3 '22: 230.3M Q4 '22: 258.4M Q1 '23: 253.5M Q2 '23: 261.2M Q3 '23: 331.8M Q4 '23: 396.8M Q1 '24: 413.5M Q2 '24: 362.9M Q3 '24: 467.2M Q4 '24: 658.4M Q1 '25: 744.9M Q2 '25: 611.1M Q3 '25: 399.4M Q4 '25: 442.9M Q1 '26: 730.8M Q2 '26: 401.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

-200M 0 200M 400M 600M Q1 '24: 308.9M Q2 '24: 316M Q3 '24: 338.1M Q4 '24: 505.9M Q1 '25: 474M Q2 '25: 360.6M Q3 '25: 219.3M Q4 '25: -29.1M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating Income Quarterly

-450M -300M -150M 0 150M 300M 450M Q3 '21: -34.5M Q4 '21: -105.8M Q1 '22: -86.9M Q2 '22: -211.1M Q3 '22: -131.4M Q4 '22: -106.8M Q1 '23: -138.1M Q2 '23: -133.5M Q3 '23: -20.8M Q4 '23: 24.6M Q1 '24: 34.9M Q2 '24: -701K Q3 '24: 22.2M Q4 '24: 161.7M Q1 '25: -300.4M Q2 '25: 115.6M Q3 '25: -103.4M Q4 '25: -411.6M Q1 '26: 358.4M Q2 '26: 13.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-600M -400M -200M 0 200M 400M 600M Q3 '21: -48.1M Q4 '21: -122M Q1 '22: -105M Q2 '22: -231.5M Q3 '22: -257.7M Q4 '22: -109.2M Q1 '23: -516.8M Q2 '23: -23.9M Q3 '23: -40.9M Q4 '23: 45.7M Q1 '24: 36.1M Q2 '24: 6.5M Q3 '24: 33.6M Q4 '24: 159M Q1 '25: -447.5M Q2 '25: 196.9M Q3 '25: -179.9M Q4 '25: -412.2M Q1 '26: 331M Q2 '26: -4.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-600M -400M -200M 0 200M 400M 600M Q3 '21: -124.3M Q4 '21: -29.3M Q1 '22: -101.2M Q2 '22: -66.8M Q3 '22: -65M Q4 '22: -92.4M Q1 '23: -209.4M Q2 '23: -122.2M Q3 '23: -114.7M Q4 '23: -54.7M Q1 '24: -242.1M Q2 '24: 14.9M Q3 '24: -70.7M Q4 '24: 92M Q1 '25: -583.4M Q2 '25: 261.3M Q3 '25: -14.6M Q4 '25: 131.2M Q1 '26: -202.7M Q2 '26: 197.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-750M -500M -250M 0 250M 500M 750M Q3 '21: -133.6M Q4 '21: -31.5M Q1 '22: -106.7M Q2 '22: -75.9M Q3 '22: -73.2M Q4 '22: -100.4M Q1 '23: -218.9M Q2 '23: -140.1M Q3 '23: -144.4M Q4 '23: -73.7M Q1 '24: -274.5M Q2 '24: -14.2M Q3 '24: -108M Q4 '24: 54M Q1 '25: -627.1M Q2 '25: 229.5M Q3 '25: -37.5M Q4 '25: 127.6M Q1 '26: -204.8M Q2 '26: 196.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '20: 76.4M Q2 '20: 78M Q3 '20: 78.5K Q1 '21: 79.5K Q2 '21: 79.7K Q3 '21: 79.9K Q1 '22: 87.3M Q2 '22: 87.5M Q3 '22: 87.6M Q1 '23: 88.2M Q2 '23: 88.7M Q3 '23: 88.9M Q1 '24: 99.1M Q2 '24: 99.1M Q3 '24: 100.4M Q1 '25: 97.4M Q2 '25: 106.6M Q3 '25: 100.2M Q1 '26: 121.9M Q2 '26: 105.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '19: -8.56 Q4 '19: -9.67 Q1 '20: -8.83 Q2 '20: -7.02 Q3 '22: -8.22 Q4 '22: -8.03 Q1 '23: -12.69 Q2 '23: -10.31 Q3 '23: -7.83 Q4 '23: -5.80 Q1 '24: 0.43 Q2 '24: 0.77 Q3 '24: 1.57 Q4 '24: 2.28 Q1 '25: -2.69 Q2 '25: -0.87 Q3 '25: -3.01 Q4 '25: -8.44 Q1 '26: -0.96 Q2 '26: -2.90 Q4 '19 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for SRPT: Cost of Revenue. Nothing in this filer's XBRL supports it for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.